|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
70,650,000 |
Market
Cap: |
4.49(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$38.62 - $89.12 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CRISPR Therapeutics is a gene editing company focused on the development of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) based therapeutics. CRISPR/Cas9 is a technology for gene editing, the process of altering specific sequences of genomic DNA. Co. is developing several gene-edited allogeneic cell therapy programs. Co.'s main product candidate, CTX001, is an investigational ex vivo CRISPR gene-edited therapy that is being evaluated for patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce fetal hemoglobin in red blood cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
19,582 |
159,721 |
159,721 |
409,721 |
Total Sell Value |
$1,173,232 |
$10,834,513 |
$10,834,513 |
$25,314,056 |
Total People Sold |
1 |
3 |
3 |
3 |
Total Sell Transactions |
1 |
12 |
12 |
22 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cagnoni Pablo J |
Director |
|
2019-11-12 |
4 |
OE |
$5.59 |
$41,925 |
D/D |
7,500 |
7,500 |
|
- |
|
Cagnoni Pablo J |
Director |
|
2019-10-30 |
4 |
AS |
$52.00 |
$390,000 |
D/D |
(7,500) |
0 |
|
- |
|
Cagnoni Pablo J |
Director |
|
2019-10-30 |
4 |
OE |
$5.59 |
$41,925 |
D/D |
7,500 |
7,500 |
|
- |
|
Bolzon Bradley J Phd |
Director |
|
2019-10-30 |
4 |
AS |
$51.89 |
$1,089,675 |
D/D |
(21,000) |
13,745 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2019-09-01 |
4 |
D |
$46.21 |
$34,195 |
D/D |
(740) |
165,061 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2019-08-02 |
4 |
D |
$52.56 |
$763,907 |
D/D |
(14,534) |
45,835 |
|
- |
|
Ho Tony W |
Executive VP, Head of R&D |
|
2019-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
60,369 |
|
- |
|
Klein Lawrence Otto |
Chief Business Officer |
|
2019-07-11 |
4 |
AS |
$50.01 |
$421,171 |
D/D |
(8,421) |
20,000 |
|
- |
|
Klein Lawrence Otto |
Chief Business Officer |
|
2019-07-11 |
4 |
OE |
$5.86 |
$49,347 |
D/D |
8,421 |
28,421 |
|
- |
|
Klein Lawrence Otto |
Chief Business Officer |
|
2019-07-10 |
4 |
AS |
$50.02 |
$579,182 |
D/D |
(11,579) |
20,000 |
|
- |
|
Klein Lawrence Otto |
Chief Business Officer |
|
2019-07-10 |
4 |
OE |
$5.86 |
$67,853 |
D/D |
11,579 |
31,579 |
|
- |
|
Novak Rodger |
President |
|
2019-07-10 |
4 |
AS |
$50.00 |
$2,500,065 |
D/D |
(50,000) |
848,007 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2019-06-17 |
4 |
AS |
$46.00 |
$920,000 |
D/D |
(20,000) |
165,801 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2019-06-17 |
4 |
OE |
$1.81 |
$36,200 |
D/D |
20,000 |
185,801 |
|
- |
|
Novak Rodger |
President |
|
2019-06-10 |
4 |
AS |
$45.00 |
$2,250,000 |
D/D |
(50,000) |
898,007 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2019-06-01 |
4 |
D |
$35.57 |
$26,357 |
D/D |
(741) |
165,801 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2019-04-29 |
4 |
AS |
$42.03 |
$840,600 |
D/D |
(20,000) |
166,542 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2019-04-29 |
4 |
OE |
$1.81 |
$36,200 |
D/D |
20,000 |
186,542 |
|
- |
|
Ho Tony W |
See Remarks |
|
2019-03-05 |
4 |
A |
$40.87 |
$408,700 |
D/D |
10,000 |
32,869 |
|
- |
|
Novak Rodger |
President |
|
2019-03-04 |
4 |
AS |
$40.24 |
$3,095,240 |
D/D |
(76,527) |
948,007 |
|
- |
|
Novak Rodger |
President |
|
2019-03-01 |
4 |
AS |
$40.01 |
$347,796 |
D/D |
(8,693) |
1,024,534 |
|
- |
|
Kulkarni Samarth |
Chief Executive Officer |
|
2019-03-01 |
4 |
D |
$39.97 |
$29,898 |
D/D |
(748) |
166,542 |
|
- |
|
Novak Rodger |
President |
|
2019-02-25 |
4 |
AS |
$40.00 |
$591,233 |
D/D |
(14,780) |
1,033,227 |
|
- |
|
Novak Rodger |
President |
|
2019-01-09 |
4 |
AS |
$35.01 |
$2,894,977 |
D/D |
(82,690) |
1,048,007 |
|
- |
|
Novak Rodger |
President |
|
2019-01-08 |
4 |
AS |
$35.09 |
$607,408 |
D/D |
(17,310) |
1,130,697 |
|
- |
|
485 Records found
|
|
Page 10 of 20 |
|
|